' INTRODUCTION
Persistent organic pollutants (POPs) in the environment can bioaccumulate and biomagnify in the foodchain. 1 POPs are consequently found in significant concentrations in adipose tissue and blood of top predators. 2 The number of reports on levels of blood accumulative pollutants (BAP) in humans 3 and wildlife 1,2 is rapidly increasing. These chemicals, such as polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs), hydroxylated PBDEs (OH-PBDEs), hydroxylated PCBs (OH-PCBs) and other halogenated phenols (OHPs), are known to interfere with the thyroid hormone (TH) system. 4 TH-disrupting compounds may compete with thyroxine (T 4 ) binding to transthyretin (TTR), one of the T 4 -transport proteins. 4, 5 Other compounds such as perfluoroalkyl substances (PFASs) have no structural similarity with THs but have a TTRbinding potency in the order of one-tenth of the endogenous T 4 . 6 TTR-binding compounds can reduce the concentrations of THs in the blood circulation of experimental animals 7 as well as in humans 8 and wildlife, 9 but the lowest dose of these contaminants causing this effect is not well established. 4 Decreased TH levels in blood might lead to subclinical hypothyroidism in adults.
Furthermore, a normal level of THs is crucial for development of the central nervous system during gestation and for general development in childhood. 4 In wildlife there is concern that THdisruption may have a negative effect on fitness of top predator species, such as the polar bear (Ursus maritimus). 10 To identify known and unknown TH-disruptors in complex environmental matrices (e.g., blood plasma), Effect-Directed Analysis (EDA) -the combined and iterative use of biological and analytical chemical techniques to direct chemical analysis to those compounds that actually have biological activity 11 -is a promising approach. For successful EDA studies of blood plasma a gentle, nondestructive, nondiscriminating sample treatment is one of the key factors to broaden the scope of EDA from abiotic to biotic matrices.
The objective of the present study was to develop and validate a method combining solid-phase extraction (SPE) and liquidÀliquid ABSTRACT: A sample preparation method combining solid-phase extraction (SPE) and liquidÀliquid extraction (LLE) was developed to be used in Effect-Directed Analysis (EDA) of blood plasma. Until now such a method was not available. It can be used for extraction of a broad range of thyroid hormone (TH)-disruptors from plasma with high recoveries. Validation of the method using spiked cow plasma showed good recoveries for hydroxylated polybrominated diphenyl ethers (OH-PBDEs; 93.8 ( 19.5%), hydroxylated polychlorinated biphenyls (OH-PCBs; 93.8 ( 15.5%), other halogenated phenols (OHPs; 107 ( 8.1%), and for short-chain (<8 C-atoms) perfluoroalkyl substances (PFASs; 85.2 ( 24.6%). In the same extracts, the potency of the compound classes spiked to the cow plasma to competitively bind to transthyretin (TTR) was recovered by 84.9 ( 8.8%. Furthermore, the SPE-LLE method efficiently removed endogenous THs from the extracts, thereby eliminating their possible contribution to the binding assay response. The SPE-LLE method was applied to polar bear plasma samples to investigate its applicability in future EDA studies focusing on TH-disrupting compounds in this top predator species that is exposed to relatively high levels of bioaccumulating pollutants. A first screening revealed TTR-binding potency in the polar bear plasma extracts, which could be explained for 60À85% by the presence of OH-PCBs.
Environmental Science & Technology ARTICLE extraction (LLE) for extraction of a broad range of known and unknown TH-disrupting compounds from plasma samples. Recoveries of a wide selection of TH-disrupting compounds from spiked cow plasma were chemically determined by gas and liquid chromatography (GC and LC) coupled to mass spectrometry (MS) and recoveries of their competitive TTR-binding activities were biologically determined in the T 4 *-TTR binding assay. 5 Furthermore, the total T 4 (TT 4 ) concentration in cow plasma before and after the extraction was measured to estimate the T 4 removal capability of the SPE-LLE method. Extracts of cow plasma samples spiked with OH-PCBs and OH-PBDEs were also fractionated using normal-phase high performance liquid chromatography (NP-HPLC) to separate xenobiotic TH-disrupting compounds from endogenous THs that could affect the bioassay results. Finally, two polar bear plasma extracts were prepared using the validated SPE-LLE method and tested in the T 4 *-TTR binding assay to demonstrate the applicability of the developed sample preparation method in further EDA studies.
' MATERIALS AND METHODS
Plasma Samples and Spiking Mixtures. Cow plasma was used for method validation because no or only very low levels of i Wellington (Guelph, Canada). j Riedel de Ha€ en (Seelze, Germany). k The combined mixture did not contain PCBs/ PBDEs (mixture 3) and PFASs (mixture 4). The spiking level in plasma indicates the concentration of the individual compounds.
Environmental Science & Technology ARTICLE contaminants were expected in this type of plasma compared to plasma from top predators, such as polar bears. Polar bear blood samples were collected from two adult (8 and 9 year old) female bears at Svalbard (Norway) in April 2008. Two mL of each plasma sample was extracted and tested in the radioligand T 4 *-TTR binding assay. These samples were selected based on their moderate TT 4 level (8 and 20 nM, respectively), high plasma lipid levels (1.5% for both), and knowledge of the plasma OH-PCB levels as determined within a much larger study (BearHealth, Web site: http://biologi.no/bearhealth-eng.htm). Further information on cow plasma preparation and on the sampling, extraction, and chemical analysis of the polar bear samples can be found in the Supporting Information.
Spiking mixtures were prepared of well-known classes of THdisrupting compounds, such as OH-PCBs, OH-PBDEs, and OHPs in hexane (J.T. Baker, The Netherlands) and PFASs in methanol (MeOH; J.T. Baker). In addition, spiking mixtures of the parent PCB and PBDE compounds were prepared in hexane. Three mL of cow plasma was spiked in a final concentration range of 0.018À0.47 μM with 30 μL of the different spiking mixtures. The final spiking concentration range was determined based on the environmentally relevant concentrations and on the analytical detection limits of the spiking compounds. In order to better mimic environmental circumstances (e.g., that BAPs might bind to blood plasma proteins) a low spiking volume (30 μL) was used to avoid direct protein precipitation by the organic solvent of the spiking mixtures. The PFAS mixture and the PFAS-spiked plasma samples were stored in polypropylene tubes to avoid interaction with glass surfaces. An overview of the individual test compounds, the mixtures and the concentrations of the individual compounds in the blood plasma after spiking is given in Table 1 . Spiked cow plasma samples, cow plasma blanks (3 mL), and procedure blanks (3 mL HPLC-grade water) were prepared in triplicate, whirl-mixed, and placed in the refrigerator (at 4°C) for overnight equilibration to enable the formation of possible bindings between the TH-disruptors and plasma proteins. To test the influence of the sample matrix on the recoveries, an additional spiking experiment was performed with 3 mL of HPLCgrade water that was spiked with 30 μL of the OH-PBDE mixture.
Sample Preparation. An overview of the experimental design of the validation study is shown in Figure 1 . The sample preparation method consists of four steps: protein denaturation, SPE, LLE, and NP-HPLC fractionation.
Protein Denaturation. To denaturate plasma proteins, formic acid (HCOOH, 99% v/v; Sigma) in 2-propanol (Sigma) (4:1, v/v) was added in a 1:1 (v/v) ratio to 3 mL of procedure blanks, spiked and blank cow plasmas, and to 2 mL of polar bear plasmas following the method described by Thomsen et al. 3 with minor modifications. The samples were whirl-mixed, sonicated in an ultrasonic bath for 10 min, and stored in the dark for 50 min at room temperature. Subsequently, 3 mL of water/2-propanol (4:1, v/v) was added to each sample (2 mL to the polar bear plasma), and the resulting mixture was sonicated for another 10 min. Finally, to reduce the influence of the organic solvent on the SPE procedure, the samples were diluted with water until the organic solvent percentage (isopropanol and solvent of the spiking mixture) was less than 5%. Typically, the total volume before SPE was 25 mL. The obtained plasma samples were clear and required no centrifugation step for pellet separation before extraction.
Solid-Phase Extraction (SPE) and Clean Up. The Oasis MCX cartridge (150 mg, 6 mL) was selected for this study, because highest chemically determined recoveries of TH-disrupting compounds was obtained for this cartridge in a pilot experiment comparing seven different cartridges (Supporting Information). Oasis MCX cartridges were conditioned with MeOH (3 mL) and equilibrated with water (3 mL) before the treated plasma samples were loaded. Solvents and samples were passed through the cartridges dropwise. The cartridges were washed with water containing 1.8% HCOOH (3 mL). After the washing step the SPE sorbent material was dried completely before elution. The adsorbed compounds were eluted from the MCX cartridges with 4 Â 0.75 mL MeOH (elution 1, E 1 ) followed by 4 Â 0.75 mL MeOH containing 5% ammonium hydroxide (NH 4 OH; Fluka, The Netherlands) (elution 2, E 2 ). Vacuum was only used after the washing step, before elution. The SPE procedure is summarized in Figure 1 .
LiquidÀLiquid Extraction (LLE). Using LLE, all E 1 and E 2 fractions were transferred into hexane that was more suitable for further analysis, except for the extracts of the plasma spiked with PFASs. Of the E 1 and E 2 fractions of these extracts, 50% was kept in MeOH, since the PFASs were analyzed on a triple quadrupole liquid chromatography electrospray ionization tandem mass spectrometer (LC-ESI-MS/MS, see Chemical Validation) using a MeOH:water (1:1, v/v) mobile phase. For LLE, the E 1 and E 2 fractions were transferred to 20 mL glass tubes with screw caps, and 5À7 mL of 4% phosphoric acid (H 3 PO 4 ; Fluka) and 2 mL of hexane were added. The addition of H 3 PO 4 improved the extraction of the hydroxylated compounds (data not shown). Subsequently, the samples were vortexed (1 min) and centrifuged (3 min; 1500 rpm). The upper hexane layers containing the compounds of interest were carefully separated and collected. The hexane fractions were then loaded onto a Pasteur pipet filled with dried sodium sulfate (Na 2 SO 4 , Promochem, Germany) to remove water, if present. The whole procedure, starting with the addition of 2 mL of hexane, was repeated another two times. For each fraction, the hexane layers were combined, and the extracts E 1, hex and E 2, hex were evaporated under nitrogen until a volume of 0.5 mL.
Normal-Phase High Performance Liquid Chromatography (NP-HPLC). To avoid interference of endogenous THs with the bioassay measurements, they were separated from the plasma extracts via NP-HPLC fractionation. Half of both the E 1, hex and E 2, hex fractions of the plasma spiked with OH-PCBs and OHPBDEs was loaded on a μPorasil NP-HPLC column (7.8 mm ID, 300 mm) packed with 10-μm μPorasil (Waters Assoc., USA), using a mobile phase gradient of hexane, dichloromethane (DCM; Promochem), and acetonitrile (ACN; J.T. Baker) at a flow-rate of 5 mL/min, as described before. 17 The 0À40 min (F 1 ) and 41À49 min (F 2 ) NP-HPLC fractions were collected, resulting in the fractions E 1 F 1 , E 1 F 2 , E 2 F 1 , and E 2 F 2 ( Figure 1 ). In these fractions recoveries (chemical analysis) and competitive TTRbinding activities (T 4 *-TTR assay) were determined. The analytes were expected to elute from the column in the first HPLC-fractions, the endogenous hormones in the second. 17 The other half of the extracts was kept unfractionated to compare the chemically determined recoveries and the biological activities of the fractionated and nonfractionated extracts. Fractionated and nonfractionated extracts were equally divided into two parts: half was exchanged into 50 μL of DMSO (Acros, Belgium) for testing in the T 4 *-TTR binding assay and half was kept in 50 μL of hexane for chemical analysis.
Endogenous Total T 4 Levels. To check the capacity of the SPE procedure to remove endogenous T 4 , TT 4 concentration was measured in the original cow plasma and in its E 1 fraction at the Academic Medical Center (AMC) Amsterdam using a radioimmunoassay, according to their validated protocol. The E 1
Environmental Science & Technology ARTICLE fraction in MeOH was evaporated under nitrogen to almost dryness and dissolved in bovine serum (Gibco, The Netherlands) stripped with T500dextran and activated charcoal. As a control, TT 4 levels were also determined in stripped serum only. The initial TT 4 concentration in polar bear plasma was measured previously within the BearHealth project using a radioimmunoassay according to Braathen et al. 9 Chemical Validation. For chemical analysis, internal standards are generally used to evaluate the analytical method performance, as for instance done by Thomsen et al. 3 However, to determine recoveries in biota extracts in bioassays or in an EDA setup, internal standards cannot be used due to their possible influence on the bioassay results. Thus, target compounds were quantified in all cases by external standard calibration by the same mixtures used for spiking.
Chemically determined recoveries of OH-PBDEs in the extracts of the spiked plasma were measured by gas chromatographyÀmass spectrometry (GC-MS) operated with electron capture negative ionization (ECNI) in the selected ion mode (SIM). Recoveries of OHPs were determined by GC-electron impact (EI)-MS operated in both SIM and full scan mode (scanning mass range: 50À400 m/z). The analysis of PCBs, PBDEs, and OH-PCBs was performed by GC with micro electron capture detection (μECD). PFASs were analyzed by LC-ESI-MS/MS. For more detailed method descriptions see the Supporting Information.
Bioassay Validation. To assess the competition between the TH-disrupting compounds in the extracts and the reference T 4 (Sigma) for binding to the T 4 -transporting protein TTR (Sigma), the extracts were tested in the radioligand T 4 *-TTR binding assay according to Lans et al. 5 with modifications as described by Hamers et al. 13 and Weiss et al. 6 The spiking mixtures were also tested directly in the assay to determine their activities in the absence of any sample matrix. The spiking mixtures, all fractions of the procedure blanks and of the extracts of the spiked and nonspiked plasma were tested in the bioassay in a dilution series (1À3À10À30À100). The extract of the plasma spiked with the combined mixture was tested in more dilutions (1À3À10À30À60À100À300) due to its expected higher activity. DoseÀresponse curves of the reference compound T 4 were fitted using a sigmoidal fit with variable slope in GraphPad Prism (version 5.01 for Windows, GraphPad Software). TTR-binding activities of the extracts were expressed as T 4 equivalent (T 4 -Eq) concentrations. For interpolation into the T 4 doseÀresponse curve (Figure 2A) , the most diluted sample was used that caused a response in the 20À50% inhibition window.
To calculate the theoretically expected TTR-binding activity of the spiking compounds (in terms of T 4 -Eq concentrations), the concentration of each spiked compound was multiplied by its relative potency factor (REP-factor). The expected total TTRbinding activity of the extract was calculated by summation of the TTR-binding activities calculated for the individual compounds in the mixture. Finally, recoveries were determined by comparing the actually measured activity of the spiked plasma extracts to i) the calculated total activity of the spiked compounds and ii) to the actually measured activities of the spiking mixtures (after transfer to DMSO). Spiking concentrations and REP factors of the test compounds are listed in Table 1 . REP factors were collected from previously published studies or were determined in the T 4 *-TTR binding assay in this study (Table 1 and 4, Figure 2B ). REP-factors were determined by the 50% inhibition concentrations (IC 50 ) of the reference compound (T 4 ) and of the test compound: REP-factor test comp = IC50 T4 / IC50 test comp .
Similarly, the theoretically expected activity of the polar bear plasma extract in the T 4 *-TTR binding assay was calculated based on the measured OH-PCB levels and the REP-factors listed in Table 4 . For the plasma samples spiked with OH-PCBs and the OH-PBDEs, both the fractions E 1, hex and E 2, hex and their subfractions after NP fractionation (E 1 F 1 , E 1 F 2 , E 2 F 1 , and E 2 F 2 ) were chemically analyzed to determine the recoveries of the individual compounds. This first recovery screening revealed that the spiked compounds eluted mainly in the first SPE fraction (E 1, hex ), while no spiked compounds or only very small amounts were detected in the second fraction (E 2, hex ). Therefore, the E 2 fractions were not further analyzed. After NP-HPLC fractionation, OH-PBDEs were found in subfraction E 1 F 1 , whereas OH-PCBs were detected mainly in the E 1 F 2 subfraction, where also the endogenous THs were expected. 17 Because relevant analytes were found in both the E 1 F 1 and E 1 F 2 subfractions and the TT 4 concentration in the plasma extract was too low to interfere with the radioligand T 4 *-TTR bioassay (see below), further chemical analyses and bioassay measurements of other samples were restricted to fraction E 1 , hex without NP-HPLC fractionation.
After SPE-LLE, the test compounds in fraction E 1, hex showed average ((SD) recoveries of 107((8.1)% for the OHPs, 93.8((15.5)% for the OH-PCBs, and 93.8((19.5)% for the OH-PBDEs (Table 2) .
For parent PCBs and PBDEs low recoveries were found (∼30%, E 1, hex , Table 2 ). Thomsen et al. 3 reported recoveries of 64À108% for the same PCBs and PBDEs in spiked serum extracted by Oasis HLB through reversed-phase hydrophobic interaction. In our cartridge selection experiment the same type of HLB cartridge was tested, but this material did not provide recoveries above 30% for these compounds (Table S2 , Supporting Information). Since the hydroxylated metabolites of PCBs and PBDEs have remarkably stronger TTR-binding affinity than their parent compounds, 4,12,18 no further effort was made to improve recovery of the parent compounds.
The recoveries of the PFASs in E 1 (for which no LLE was done prior to chemical analysis) decreased with carbon atom chain length from 115% to 2%, with acceptable recoveries 85.2((24.6)% for the most potent, short chain (<8 C-atoms) PFASs, independent of the type of their polar group (Table 2) .
Biologically Determined Recoveries. In the TTR-assay, all extracts of plasma spiked with the different compound classes showed activity in accordance with the chemically determined (Tables 2 and 3) .
For extracts of plasma samples spiked with OH-PCBs, TTR-binding activities were mainly found in the E 1, hex fraction, especially in its second subfraction E 1 F 2 (Figure 2  C ). An activity of 0.52 μM T 4 -Eq was found in the E 1, hex , which is in good agreement with the calculated activity (0.50 μM T 4 -Eq; 104% recovery) and with the measured activity in the spiking mixtures (0.58 μM T 4 -Eq; 90% recovery) ( Table 3) .
For extracts of plasma samples spiked with OH-PBDEs, TTRbinding activities were also found in the fraction E 1, hex , but in its first HPLC fraction E 1 F 1 ( Figure 2D ). The measured activity in the E 1 (0.41 μM T 4 -Eq) was in line with the calculated (0.48 μM T 4 -Eq) and measured (0.49 μM T 4 -Eq) activities, resulting in recoveries >84% (Table 3) .
The activities found in the extracts of plasma samples spiked with the OHPs (1.51 μM T 4 -Eq) were in accordance with the measured activity in the spiking mixture (77% recovery) and with the calculated activity (82%; Table 3, Figure 2E ). The extracts of a These values are below the Limit of Detection (LOD), which is 0.016 μM T 4 -Eq (∼20% T 4 * binding to TTR). b The spiking mixture was measured in the assay after transfer into DMSO.
c Calculated activities are determined based on the T 4 REP-factors of the spiking compounds and their actual concentration in the spiked plasma.
d Results are expressed in μM T 4 -Eq in plasma and compared to the measured activity in the spiking mixtures and to the calculated activities as recoveries (%). n.d., not detected; "-", not calculated. plasma spiked with the combined mixture of OH-PCBs, OHPBDEs, and OHPs showed an activity of 2.05 μM T 4 -Eq, in good agreement with the measured activity in the spiking mixture and with the calculated activity (>78% recovery; Table 3 , Figure 2E) .
PCBs, PBDEs, and PFASs are less potent TH-disruptors than OH-PCBs, OH-PBDEs, and OHPs and consequently also have lower REP values ( Table 1 ). The calculated total potencies for the extracts of the plasmas spiked with both PCBs and PBDEs (3 nM T 4 -Eq) and with PFASs (10 nM T 4 -Eq) were below 16 nM T 4 -Eq, which is the limit of detection (LOD) in the assay. Consequently, no activity was detected in the extracts of plasma spiked with PCBs, PBDEs, and PFASs (Table 3) .
All (sub)fractions of the blanks were tested for competitive TTR-binding activity. Neither the procedure blanks nor the plasma blanks showed any activity. In the extract of the water spiked with OH-PBDEs, a similar activity (0.40 μM T 4 -Eq) was found as in extract of the plasma spiked with the OH-PBDEs (0.41 μM T 4 -Eq), indicating that the eventually remaining sample matrix constituents do not suppress or enhance the TTR-binding activities of the spiked compounds in the plasma extracts.
Endogenous TT 4 Levels. The presence of endogenous hormones in biota extracts may interfere with the measurement of endocrine disrupting compounds in in vitro bioassays. 17, 19 Therefore, NP-HPLC fractionation was initially used to separate endogenous hormones from POPs in biota extracts as was previously done in studies on estrogens in blood matrices 20 and androgens and THs in fish tissues. 17 The NP-HPLC elution profile of the spiking compounds (data not shown) revealed that OH-PCBs eluted in the same subfraction (E 1 F 2 ) as the endogenous THs. 17 However, after SPE about 95% of the initial TT4 concentration (65 nM) was removed from the cow plasma. Taking all the concentration and dilution steps in the T4*-TTR binding assay protocol into account, the remaining 3 nM TT 4 , determined in the E 1 fraction, corresponds to 5.6 nM T 4 -Eq in the assay. According to the T 4 calibration curve, covering a concentration range of 0À1024 nM T 4 (Figure 2A ), this concentration was below 16 nM T 4 -Eq, which is the LOD in the assay and too low to influence the measured activities in extracts of the spiked samples. In the polar bear plasma, even lower initial TT 4 concentrations (8 and 20 nM, respectively) were measured, again indicating no influence on the bioassay result. Therefore, we did not apply further NP-HPLC fractionation for TH removal from the extracts of other spiked cow plasma samples or nonspiked polar bear plasma samples.
Assuming that (95% of plasma TT 4 is removed during the SPE procedure, TT 4 levels for e.g., monkey, seal, fish, and dolphin were taken from the literature, 21À24 and their possible influence on the assay was calculated when extracting a 3 mL sample (the sample volume for which the developed method was validated). For all studied species, the calculated T 4 -Eqs were already below the lowest T 4 level (16 nM) that caused an effect in the 3-fold diluted extracts (Table 5) . So, further dilution will lead to an even lower T 4 level in the extracts with no influence on the bioassay results. This indicates that the contribution of endogenous T 4 does not lead to overestimation of the measured TTRbinding activity in plasma extracts from different species, which emphasizes the broad scope of the SPE-LLE method and its suitability for inclusion in EDA strategies.
Polar Bear Plasma. The SPE-LLE method successfully extracted the biologically active compounds present in the polar bear plasma samples and the activities, known to be partly caused by a suite of chemically determined OH-PCBs, could be measured in the T 4 *-TTR binding assay. This is in accordance with a previous study that showed that in polar bear plasma, 4-OH-CB107 had a high binding affinity to TTR. 25 In the first polar bear plasma extract, the calculated TTR-binding activity caused by the OH-PCBs (1.1 μM T 4 -Eq) could explain 85% of the actually measured TTR-binding activity (1.3 μM T 4 -Eq). In the lowest level of thyroxine (T 4 ) in the assay causing effect: 16 nM a A 3 mL plasma sample was reduced to a 40 μL extract in DMSO; diluted 40-times in the assay; 5% recovery of T 4 was expected. These calculated concentrations can be compared to the lowest level of T 4 causing effect in the assay (Figure 2A ).
second extract, the calculated activity (0.9 μM T 4 -Eq) could explain 60% of the measured activity (1.5 μM T 4 -Eq). The measured activities in the polar bear plasma extracts (E 1, hex ) were higher than the expected activities based on calculations using the OH-PCB REP values and the measured ∑OH-PCB concentrations (Table 4) . This might indicate the presence of other TH-disrupting compounds. Method Applicability. The good (71À120%) recoveries determined by chemical analysis for various potent THdisruptors (OH-PCBs, OH-PBDEs, OHPs, and short-chain PFASs except PFBA) in combination with good recoveries (77À104%) determined in extracts of plasma spiked with these compounds in the bioassay demonstrate the applicability of the developed plasma sample preparation method in e.g., an EDA study.
The relative standard deviations (RSDs (%)) obtained for the chemically analyzed recoveries of the different classes of compounds ranged from 1.4 to 24.8%, while for bioassay measurements RSDs of 3.3 to 8.3% were obtained.
After the chemical and biological validation of the SPE-LLE plasma sample preparation method and a pilot study on two polar bear plasma samples, a larger number of polar bear plasma samples (n = 30) have been extracted in collaboration with the Norwegian University of Science and Technology (NTNU), in the framework of the BearHealth-project. Three polar bear plasma samples showing a combination of high competitive TTR-binding activity in the TTR assay with low levels of target analyzed THdisrupting compounds were selected for further studies to identify the compounds causing the unexplained TTR-binding activities in the samples. This work is currently carried out in a study design based on EDA, using high resolution mass spectrometry to identify the unknown TH-disrupting compounds. 
